Company evaluating potential acquisitions and in-licensing opportunities to drive next phase of strategic development Cash position of $76.3 million as of December 31, 2025 expected to fund current operating plan beyond 2027 DALLAS, March 27, 2026 (GLOBE NEWSWIRE) — Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its fourth quarter and full year 2025 financial results and provided a corporate update. Recent Highlights:In January 2026, Axion Bio, Inc., a wholly owned subsidiary of Instil, discontinued clinical development of AXN-2510 and entered into a termination agreement with ImmuneOnco Biopharmaceuticals (Shanghai) Inc. to terminate the license and collaboration agreement for AXN-2510 and AXN-27M. Following this decision, Instil...

Completed a US$57.2 million equity financing; commenced trading on the Nasdaq Global Market under the ticker “MSLE” on Feb. 6, 2026Secured global regulatory clearances and initiated BASECAMP, a placebo-controlled Phase 2 clinical trial of SAT-3247 in boys aged 7 to less than 10 years living with Duchenne muscular dystrophy (“Duchenne” or “DMD”)Presented initial functional outcomes from 56 days of treatment in TRAILHEAD (follow-on trial to CL-101) at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, demonstrating that grip strength improvements observed in CL-101 were maintained or improved in TRAILHEAD over an aggregate period of 9 to 13 monthsReported proteomic data from CL-101 (28-day Phase 1b trial in adults with DMD) at MDA, showing reductions in established biomarkers of muscle degeneration...

Record Quarterly Revenues of $737.6 Million, a 34.6% Increase from a Year Ago Quarterly Adjusted EBITDA (non-GAAP) Increased 53% from Prior Year1 Record Total Backlog and Awards of $3.7 Billion, 49% Increase from a Year Ago, with Robust Q4 Book-to-Bill of 1.9x Tuck-In Acquisition of Seattle Area-Based Engineering Firm Establish First Quarter 2026 Guidance for Revenue of $925 Million – $950 Million and Non-GAAP Adjusted EBITDA of $90 Million – $100 Million Raise Full Year 2026 Guidance for Revenue to $3.7 Billion – $3.9 Billion and Non-GAAP Adjusted EBITDA of $400 Million – $430 Million SAN JOSE, Calif., March 27, 2026 (GLOBE NEWSWIRE) — Legence Corp. (Nasdaq: LGN) (“Legence” or the “Company”) today reported financial results for the fourth quarter and year ended December 31, 2025. “Our fourth quarter 2025...

AUCATZYL® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025 AUCATZYL® UK launch underway following successful National Institute for Health and Care Excellence (NICE) evaluation Autolus continues to expect full year 2026 AUCATZYL® net product revenue of $120 million to $135 million and shift to positive gross margin to occur in 2026 Independent real-world AUCATZYL® data from ROCCA consortium confirm high level of clinical activity with favorable safety profile Pivotal Phase 2 clinical trials with obe-cel in ​lupus nephritis and pediatric ALL enrolling; initial clinical data from BOBCAT Phase 1 trial in progressive MS anticipated by year-end 2026 Conference call to be held today at 08:30 am EDT/12:30 pm GMT: conference call participants should pre-register...

Company continues to evaluate strategic options to maximize shareholder value WATERTOWN, Mass., March 27, 2026 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2025. “We have initiated a process to explore a range of alternatives available to the Company to maximize stockholder value,” said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf. “Such measures may include, among other options, a sale of the Company, a business combination...

Trax Park opening – Darren Leigh and Lord Peter HendyTrax Park officially opened by the Rail Minister, Lord Peter HendyUnipart Chief Executive Darren LeighUnipart Chief Executive Darren LeighUnipart CowleyUnipart CowleyUnipart announces their 2025 financial results.Highlights:Group Turnover reached £991.6m Underlying PBIT of £27.9m Strengthened balance sheet – ended year with positive net cash of £9.4m, and our net assets increased by 22.0% to £145.6m Ranked top logistics provider in the Chartered Institute of Logistics and Transport’s Top 30 list Maintained world-class safety performance Continued delivery of net zero commitments through reducing carbon emissionsOXFORD, United Kingdom, March 27, 2026 (GLOBE NEWSWIRE) — Unipart, the supply chain performance improvement partner,...

SHENZHEN, China, March 27, 2026 (GLOBE NEWSWIRE) — Huize Holding Limited, (“Huize”, the “Company” or “we”) (NASDAQ: HUIZ), a leading insurance technology platform connecting consumers, insurance carriers, and distribution partners digitally through data-driven and AI-powered solutions in Asia, today announced its unaudited financial results for the second half and full year ended December 31, 2025. Full Year 2025 Financial and Operational HighlightsRecord-breaking insurance premiums: Both first year premiums (“FYP”) and gross written premiums (“GWP”) reached record highs of RMB4,630.8 million and RMB7,427.1 million in 2025, representing robust increases of 35.4% and 20.6% year-over-year, respectively. This remarkable performance was primarily driven by our high-quality customer base, consistently strong persistency ratios, and...

Press Release Estimated Operational Results Full Year 2025 Vantiva meets its guidance at the budget forex rate ADJUSTED EBITDA: €145 MILLION vs €109 million in 20241(€155 MILLION at budget forex rate)FCF2 POSITIVE: €62 MILLION vs -€25 million in 2024(€71 MILLION at budget forex rate) Paris (France) – March 27, 2026 – Vantiva (Euronext Paris: VANTI), a global technology leader in connectivity, announces its estimated unaudited operational results for the year 2025. The accounting basis used for these estimates is consistent with the accounting methods applied by Vantiva and described in its consolidated financial statements. However, since some annual closing procedures for 2025 are not yet completed, the auditors’ opinion is still pending. The estimated financial data has been reviewed by Vantiva’s Board of Directors and is currently...

Read the entire full-year 2025 results press release hereLouvain-la-Neuve, Belgium, 27 March 2026 – IBA (Ion Beam Applications S.A.), today announces its consolidated results of 2025 financial year, with strong execution across the businesses. Robust commercial momentum, notably in Proton Therapy, resulted in a historic order intake and a new all-time high backlog. Delivered in line with guidance, the year marks continued progress in the execution of IBA’s strategic roadmap to the benefit of all its stakeholders.Record-high revenue and enhanced profitabilityNet sales rose 24% vs. 2024, to €620 million, thanks to well-executed backlog conversion in IBA Clinical (+44% net sales growth) Gross margin decreased to 32.2% vs. 33.7% in 2024, driven by less favorable equipment profitability mix (including legacy low-margin projects...

Q4 2025 revenues were $13.4 million, up 29.7% from Q4 2024. This was an all-time quarterly record for the Company. Full year 2025 revenues were $44.1 million up 35.0% from full year 2024 revenues. This was an all-time annual record for the Company. Q4 2025 gross margin was 74.7%, versus 77.9% in Q4 2024 and 77.6% in Q3 2025. Full year 2025 gross margin was 77.1% versus 75.2% in 2024. GAAP Operating Income was $2.0 million for Q4 2025 and $4.9 million for full year 2025. Company provides guidance for revenues of $9.6-10.3 million (an increase of 3-10%) for Q1 2026 as compared to Q1 2025 and initiates full year 2026 revenue guidance of 16-25% growth vs 2025 ($51.0-55.0 million). EDEN PRAIRIE, Minn., March 26, 2026 (GLOBE NEWSWIRE) — Sanuwave Health, Inc. (the “Company” or “Sanuwave”) (NASDAQ: SNWV), a leading...